Richard Scolyer Dies at 59 After 3-Year Glioblastoma Fight
Updated
Updated · BBC.com · Jun 7
Richard Scolyer Dies at 59 After 3-Year Glioblastoma Fight
3 articles · Updated · BBC.com · Jun 7
Summary
Richard Scolyer, the Australian pathologist who turned his own glioblastoma into a test case for treatment, died three years after his diagnosis, according to a farewell letter released after his death.
In 2023, Scolyer became the first brain-cancer patient to receive combination immunotherapy before surgery, plus a personalized vaccine, adapting melanoma breakthroughs he developed with colleague Georgina Long.
Subsequent scans suggested an immune response in his brain, and those early findings have already led to an early-stage U.S. clinical trial seeking to replicate the approach.
Scolyer and Long, co-directors of Melanoma Institute Australia, were named 2024 Australian of the Year after helping lift advanced melanoma outcomes so that about half of patients are now essentially cured, up from under 10%.
In his final message, Scolyer urged scientists to keep pushing boundaries and governments to keep funding innovation, framing his own case as a way to keep contributing even in his darkest hour.
Dr. Scolyer's trial showed promise. How soon will we know if his immunotherapy can actually cure this deadly brain cancer?
What does this top doctor's courageous journey truly mean for the future of cancer research and patient-led science?
His personalized treatment was revolutionary. Can this expensive, bespoke approach ever become a mainstream cure available to everyone?
Defying Glioblastoma: Richard Scolyer’s Journey, Experimental Immunotherapy, and the $5.9 Million Chair Accelerating Brain Cancer Research
Overview
Professor Richard Scolyer, diagnosed with glioblastoma in 2023, became a symbol of hope by bravely stepping forward as 'patient zero' for a world-first brain cancer treatment. Despite facing multiple tumor recurrences and describing his journey as 'tough,' he inspired many through his openness and resilience. Recognized as the 2024 Australian of the Year, his legacy was further cemented by the establishment of the $5.9 million Richard Scolyer Chair in Brain Cancer Research. His passing on June 7, 2026, brought an outpouring of grief and gratitude, highlighting his profound impact on brain cancer research and advocacy.